Key takeaways
- An injected or infused peptide preparation derived from purified pig brain tissue, described as neurotrophic and neuroprotective and used clinically in parts of Europe and Asia for decades.
- The most-studied peptide of its kind, with multiple meta-analyses and phase 4 trials across stroke, traumatic brain injury, and vascular dementia.
- Meta-analyses report benefit on early post-stroke neurological scores, after moderate-to-severe TBI, and in vascular cognition.
- The most rigorous review, a Cochrane meta-analysis of seven trials in acute ischaemic stroke, found no benefit on death or disability and a possible safety signal.
- An active phase 2 trial (CERICA) is testing it in CADASIL, a genetic small-vessel brain disease.
What Cerebrolysin Is
Unlike most peptides marketed for the brain, Cerebrolysin has an unusually large clinical literature behind it: multiple randomized trials and pooled analyses across several conditions, which means it can be judged by the evidence rather than by marketing claims. That evidence turns out to be mixed, which is the more interesting story.
The compound itself is a neuropeptide preparation made from purified pig brain tissue. It contains a mixture of low-molecular-weight peptides and free amino acids, and it is given by injection or infusion rather than as a pill. It has been used clinically in parts of Europe and Asia for decades, primarily in conditions affecting the brain such as stroke, traumatic brain injury, and dementia.
How It Is Thought to Work
Cerebrolysin is described as neurotrophic and neuroprotective. Its peptide fractions appear to mimic the action of naturally occurring nerve growth factors, supporting the survival of neurons and helping regulate processes involved in brain repair after injury. Researchers have also explored whether it influences the clearance of harmful protein fragments and reduces inflammatory damage in the brain.
Much of this mechanistic understanding comes from laboratory and animal research. A plausible mechanism is a reason to study a compound, not proof that it works in people, which is why the human trials below matter most.
A Mixed Clinical Picture
Start with the strongest evidence and work down. The most rigorous review is the Cochrane meta-analysis of Cerebrolysin for acute ischaemic stroke, updated in 2020 and again in 2023. Across seven randomized controlled trials it found that Cerebrolysin probably makes little to no difference to all-cause death, and it flagged a possible increase in non-fatal serious adverse events. Cochrane reviews sit at the top of the evidence hierarchy, so this null result carries the most weight of anything here.
Other meta-analyses are more encouraging but come with consistent caveats about study quality. A 2018 pooled analysis of nine randomized controlled trials in early post-stroke recovery (Neurological Sciences) reported a beneficial effect on early neurological scores measured by the NIH Stroke Scale, with safety comparable to placebo. A 2021 prospective meta-analysis of the CAPTAIN trial series in moderate-to-severe traumatic brain injury (Neurological Sciences) found a small-to-medium effect favoring Cerebrolysin on functional and neuropsychological outcomes at 30 and 90 days. And a 2019 Cochrane review of Cerebrolysin for vascular dementia found a cognitive and global-function signal, though the supporting trials were rated as low quality.
The trial registries show what is still being tested. The CASTA trial, a phase 4 study of 1,071 acute ischaemic stroke patients, and a phase 4 vascular dementia trial of 242 patients sit behind much of the pooled data above. The CERICA trial, a phase 2 placebo-controlled study, is now testing Cerebrolysin in CADASIL, a genetic small-vessel brain disease that drives early vascular cognitive decline.
So the positive signals in early stroke recovery, TBI, and vascular cognition sit alongside a null result from the single most rigorous review, against a backdrop of variable trial quality. These are informative early findings, not settled conclusions.
Who It's Being Studied In
The research centers on brain injury and cognitive decline: recovery after stroke, the aftermath of moderate-to-severe head trauma, and forms of vascular cognitive impairment. These are serious clinical situations managed by neurologists and other specialists, not areas for self-experimentation.
Because the evidence is mixed and the safety picture in acute stroke raised some concerns, whether Cerebrolysin is appropriate for any individual is not a question this article can answer. That determination belongs with a qualified physician who can weigh a person's specific diagnosis, history, and the current state of the evidence.
The evidence
Selected references, each verified against primary sources (PubMed and ClinicalTrials.gov). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Cerebrolysin is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.